Press Releases
2024
October 8, 2024
ImmuneSensor Therapeutics Initiates Dosing in Phase 1 Clinical Trial of Lead cGAS Inhibitor Drug Candidate, IMSB301
September 17, 2024
ImmuneSensor Therapeutics Granted New U.S. Patent for its Oral cGAS Inhibitors
September 16, 2024
ImmuneSensor Therapeutics to Participate in the UBS 2024 Virtual Biotechnology Private Company Symposium